185 related articles for article (PubMed ID: 25586166)
1. Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer.
Todenhöfer T; Hennenlotter J; Faber F; Wallwiener D; Schilling D; Kühs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Fehm T; Stenzl A; Schwentner C
Prostate; 2015 May; 75(6):637-45. PubMed ID: 25586166
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
3. Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy.
Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Porcell J; Dueñas R
Int J Mol Med; 2012 Oct; 30(4):896-904. PubMed ID: 22825050
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
6. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
7. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
8. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD
Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
11. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
13. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
[TBL] [Abstract][Full Text] [Related]
14. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy.
Berg A; Berner A; Lilleby W; Bruland ØS; Fosså SD; Nesland JM; Kvalheim G
Int J Cancer; 2007 Apr; 120(8):1603-9. PubMed ID: 17230512
[TBL] [Abstract][Full Text] [Related]
15. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
[TBL] [Abstract][Full Text] [Related]
17. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
18. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.
Reese AC; Cooperberg MR; Carroll PR
J Urol; 2010 Jul; 184(1):114-9. PubMed ID: 20478578
[TBL] [Abstract][Full Text] [Related]
19. Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients.
Lilleby W; Stensvold A; Mills IG; Nesland JM
Int J Cancer; 2013 Jul; 133(1):149-55. PubMed ID: 23280694
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
